A novel technology enabling efficient delivery of personalized probiotics to prevent gut-related diseases and recover damaged gut microbiota

Project Information

MBSelect

Grant agreement ID: 945936

DOI 10.3030/945936

Closed project

EC signature date 6 May 2020

Start date 1 June 2020

End date 30 November 2022

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost € 2 875 932,00

EU contribution € 1 995 700,00

Coordinated by

MYBIOTICS PHARMA LTD
Israel